On the above two Weekly chart price action has corrected almost 90% since June 2020. A number of reasons now exist to be bullish , including: 1) A strong buy signal prints (not shown). 2) Regular bullish divergence . Multiple oscillators printing divergence. 3) Price action confirms support on past resistance. 4) Falling wedge breakout + backtest. Is it possible...
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer, infectious diseases and autoimmune diseases
- Inverse head and shoulders pattern playing out on the trendline support - Tipranks analyst consensus $31 Target of 121% upside - Recent insider purchases, always a good sign - CUE-101 Phase one is looking very promising
Just thought I would create a quick video to show how easy it is to buy and sell stocks within Trading View. I use Trade Station as the broker - Note: You need to use the US Trade Station. I dont think the International Trade Station works with Trading View. If you would like to sign up to Trading View would be great if you could use my link so we both get $30...
If you understand the idea, push a thumb up! Have a question? Don't be shy to ask!
If you understand the idea, push a thumb up! Have a question? Don't be shy to ask!
Cue has been having a great run of late - up 100% over the last month and up a bit over 200% over the last 6 months. Its been running pretty hard for a while so might be overextended, but I like what they do and could be worth a watch. Be careful of pullbacks. Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable...
On breakout alert today. Looking for entry on backtest and confirmation of support Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes...
Testing all-time highs. Big volume coming in since the last earnings call. Would like to see a break of $17.50 to go long.
Ready to run after a higher low?